PwC IPO Lead Discusses Market Selectivity, AI Values And 2027 Outlook
PwC IPO services leader Mike Bellin discusses the current U.S. IPO market, highlighting investor selectivity, AI valuations, biotech resurgence, and key factors for a strong market outlook.
The U.S. IPO market has bounced back, though the recovery remains uneven. Companies pursuing public listings face investors who are prioritizing durable revenue, profitability, and reasonable valuations, while general uncertainty has led some issuers to delay their offerings.
Mike Bellin, a partner and U.S. IPO services leader at PricewaterhouseCoopers, views the current market as open to businesses that possess the appropriate scale, financial metrics, and preparation.
During a recent discussion with Crunchbase News, Bellin addressed the recent cooling of IPO momentum, public investor evaluation standards for artificial intelligence companies, the resurgence of biotech, and the renewed interest in SPACs. He also shared his perspective on what factors could pave the way for a stronger start to 2027.
This interview has been edited for length and clarity.
Crunchbase News: How healthy is the IPO market right now?

Bellin: A typical healthy IPO year in the United States features anywhere from 125 to 175 traditional IPOs, and year to date we have recorded just under 90.
The overall breadth of the market indicates that it has been healthy. We have witnessed industrial products return to the market alongside tech, consumer markets, energy, utilities, and select financial services.
For the majority of the first three quarters of the year, the IPO landscape was quite strong and broad. However, momentum has slowed down significantly since September and October.
Is the market in trouble? I would say no. It is simply very selective and far from closed. Quality issuers with proper readiness, the right narrative, and sound metrics are still able to complete their deals.
What has contributed to the slowdown?
Bellin: The macro environment broadly served as the main driver, encompassing interest rates, inflation, and geopolitical concerns. Simply put, that uncertainty acted as a major factor.
Another significant factor I have observed is valuation. Certain transactions and offerings pursued fairly aggressive valuations, and given all the uncertainties mentioned, the market evaluated those price tags and likely deemed them a bit rich.
Consequently, many issuers chose to hit the pause button and wait for another window to open.
What are public market investors looking for?
Bellin: Investors are primarily searching for durable revenue—revenue underpinned by robust, diverse customers and a growing top line. This revenue reliability, backed by a significant backlog of demand for the IPO issuer’s products and services, consistently serves as a strong indicator.
Leverage is another critical element. For companies carrying substantial leverage in a rising-rate environment, key questions include whether they can take on new leverage to create profitable future value opportunities and whether they can refinance existing debt given higher rates.
Entering the capital markets with a sensible leverage ratio, or clearly explaining through your equity story how you intend to generate a return on debt-invested capital, makes a dramatic difference.
Is the market open to a broad range of venture-backed startups, or primarily larger companies?
Bellin: Scale matters greatly. Companies possessing that scale—whether measured by revenue or assets, depending on the sector—stand out significantly. These are the organizations that can practically dictate their optimal listing window and perform well.
Conversely, some smaller enterprises, midmarket companies, and small-cap firms—excluding life sciences and biotechs—have encountered more challenges.
If a company is growing at an appropriate rate and demonstrating solid metrics, the IPO market remains fully accessible. However, for those on the lower end of the scale, opportunities to enter the market may be restricted.
Will enthusiasm for AI companies carry into public markets, or will investors be more skeptical?
Bellin: Investors are not inherently skeptical of AI; rather, they are skeptical of spending that lacks visibility into future earnings and revenue durability.
The market is actively distinguishing between AI companies with demonstrable demand and those relying solely on a narrative. Backlog, growth, and confirmed demand are critical differentiators.
Another key element in today’s market is cash generation and profitability. If a company lacks profitability, the market looks at when that profitable period will arrive. Profitability can be measured in various ways, including GAAP income, EBITDA, cash flows, free cash flows, and levered free cash flows available to the business.
We have never before witnessed a development and growth cycle quite like this one. It is exhilarating, but the market will undoubtedly differentiate between enterprises that are worthy of being public companies and those that are not.
What does the uneven performance of newly public companies signal?
Bellin: It signals a high degree of selectivity. While there have been major winners in the IPO market, other offerings have not traded as strongly post-issuance as many anticipated.
Companies coming to market must carefully weigh their valuations and pricing strategies. Pursuing overly aggressive pricing can cause a stock to trade down following the IPO, which negatively impacts key metrics.
Overall, strong candidates continue to emerge, and given the prevailing volatility, companies are arriving at the market better prepared than ever before.
What is driving biotech’s resurgence?
Bellin: The M&A market for many of these companies is currently robust. As major healthcare corporations lose patent protections on profitable drugs, they look toward the next generation of development to secure future value.
Many of these biotech firms were acquired by large pharmaceutical companies even prior to reaching the public markets. Competition for these assets creates a balanced trade-off between an IPO opportunity offering substantial upside and an M&A exit providing greater day-one certainty.
Ultimately, mergers and acquisitions serve as the engine powering the resurgence of IPOs within this sector.
Within the public markets, many of these assets have traded exceptionally well, generating a vital momentum and flywheel effect. We have observed this flywheel operating within biotech, whereas the rest of the broader market has lacked it over the past few months.
Why are SPACs attracting renewed interest?
Bellin: Amid market volatility, we are seeing an uptick in discussions surrounding SPACs. Because special purpose acquisition companies establish valuation certainty on day one, an enterprise pursuing a SPAC exit has a clear understanding of the potential cash inflow, subject to variables like redemptions.
Another factor supporting a healthy SPAC market is the presence of serial SPAC sponsors. These experienced participants understand the product, recognize what constitutes a viable de-SPAC candidate, and can properly assess whether a target company is prepared to scale and hit the milestones outlined in offering documentation.
The market is healthier and more mature today than in past cycles. Even so, given the substantial inventory of SPACs currently seeking targets, many remain actively on the hunt.
What do you expect in 2027?
Bellin: Hundreds of companies are sitting in the pipeline, prepared to launch once market conditions allow. The trajectory for the remainder of 2026 and the opening of 2027 depends heavily on market momentum.
I remain an eternal optimist. Buy-side demand is robust, and significant capital remains available for the right businesses. If we can foster momentum through the closing months of 2026, I anticipate a strong start to 2027.
The AI ecosystem remains healthy, energy demand is consistently significant, and qualified energy companies are making their way to the market. Consumer and industrial products are also staging a comeback.
Private equity firms have maintained high levels of activity throughout 2026, and I expect that trend to persist into 2027.
We are positioned for a strong year ahead, though selectivity will remain the defining theme.
Related Crunchbase query:
- Global IPOs For Venture-Backed Companies In 2026
?Frequently Asked Questions
01What is the typical volume of traditional IPOs in a healthy U.S. market?
According to Mike Bellin, a healthy U.S. IPO market typically sees between 125 and 175 traditional IPOs in a given year.
02Why have some companies chosen to delay their IPO plans?
Uncertainty surrounding macroeconomic factors like interest rates, inflation, and geopolitical issues—combined with aggressive valuation expectations—has caused some issuers to hit pause and wait for better market windows.
03What key traits are public market investors prioritizing in IPO candidates?
Investors are looking for durable revenue supported by diverse customers, strong backlogs of demand, manageable leverage ratios, and clear paths to profitability and cash generation.
04How are investors evaluating artificial intelligence companies?
Investors are looking past mere AI narratives and focusing instead on companies that demonstrate visible demand, concrete revenue growth, backlogs, and clear visibility into future earnings.
Illustration: Dom Guzman



